Home / Expertise / Life Sciences & Healthcare

Life Sciences & Healthcare


We work with and have established long-term relationships with the top 100 life sciences and healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our life sciences and healthcare teams in Central and Eastern Europe advise leading global business groups in the sector on transactions, commercial agreements, compliance, investigations and litigation, very often across multiple jurisdictions in the region and beyond. We can help you to navigate the regulatory landscape and to ensure compliance with both local laws and global policies.

Our co-operation with the team was delightful.
Chambers, 2016

With over 150 international specialist lawyers across CMS and the support of the Life Sciences & Healthcare Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your life sciences and healthcare business. Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics.

With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the life sciences and healthcare sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice.

In Poland we are one of the largest players in the market. The close cooperation of almost 150 lawyers in our Warsaw and Poznan offices allows the Life Sciences & Healthcare Practice to offer comprehensive industry-focused advice. Our clients trust us with their toughest business challenges, spanning from clinical trials, pricing and reimbursement, IP, to high profile compliance issues and M&A transactions.

Read more Read less
High­lights of our ex­per­i­ence in Lifes­ci­ences in Po­land
A lead­ing glob­al med­ic­al device and phar­ma­ceut­ic­al com­pany on reg­u­lat­ory is­sues con­cern­ing both med­ic­al devices and medi­cin­al products, in such areas as com­pli­ance, re­im­burse­ment, mar­ket­ing, pro­mo­tion and dis­tri­bu­tion.Nu­mer­ous phar­ma­ceut­ic­al com­pan­ies on stra­tegic pro­jects com­pris­ing com­plex com­pli­ance is­sues, in­clud­ing identi­fy­ing risks and pro­pos­ing an en­tirely new mod­el of busi­ness or­gan­isa­tion. Provid­ing a gen­er­al re­view of the cli­ent’s edu­ca­tion­al and mar­ket­ing strategies, as well as a com­plex audit of rel­ev­ant doc­u­ment­a­tion.Re­cord­ati on the ac­quis­i­tion of Farma-Pro­jekt, a Pol­ish phar­ma­ceut­ic­al com­pany.A UK lis­ted phar­ma­ceut­ic­al com­pany on reg­u­lat­ory and nuc­le­ar re­quire­ments for pla­cing a med­ic­al device con­tain­ing ra­dio­act­ive iso­topes on the Pol­ish mar­ket. Our ad­vice covered the reg­u­lat­ory ob­lig­a­tions for med­ic­al devices, nuc­le­ar safety re­quire­ments and au­thor­isa­tions for ra­dio­act­ive products, as well as the ob­lig­a­tions of hos­pit­als which in­tend to ad­min­is­ter/use ra­dio­act­ive products in Po­land.An Amer­ic­an on­co­logy com­pany on reg­u­lat­ory is­sues re­gard­ing orphan medi­cin­al products and oth­er leg­al mat­ters, as well as co­ordin­at­ing work in a num­ber of CEE jur­is­dic­tions.Henry Schein Inc. on the ac­quis­i­tion of shares in Me­div­et S.A., the pro­vider of an­im­al health products.Please down­load the print ver­sion be­low.


Show only
30 October 2019
CMS ad­vises Ad­vent In­ter­na­tion­al and Zentiva on ac­quis­i­tion of Al­vo­gen’s...
CMS ad­vises Ad­vent In­ter­na­tion­al and Zentiva on ac­quis­i­tion of Al­vo­gen’s CEE busi­ness. Find out more.
20 April 2020
CMS Ex­pert Guide to Ad­vert­ising of Medi­cines and Med­ic­al Devices
This Ex­pert Guide provides high level in­form­a­tion on life sci­ences and health­care ad­vert­ising in 27 jur­is­dic­tions and of­fers a quick and simple un­der­stand­ing of the ap­plic­able laws. The Ex­pert Guide cov­ers, amongst oth­ers, dif­fer­ent types of ad­vert­ising, reg­u­lat­ory as­pects as well as leg­al con­sequences of non-com­pli­ance.
26 May 2020
European Com­mis­sion must ad­dress in­tel­lec­tu­al prop­erty and AI
The Com­mit­tee on Leg­al Af­fairs (JURI) of the European Par­lia­ment has pub­lished three draft re­ports re­lat­ing to ar­ti­fi­cial in­tel­li­gence (AI). This note is about the draft re­port on in­tel­lec­tu­al prop­erty...
9 October 2017
CMS Po­land launches law com­pet­i­tion for stu­dents
CMS Po­land is in­vit­ing third, fourth and fifth year law stu­dents to take part in a law com­pet­i­tion. Par­ti­cipants have to come up with the best solu­tion to a leg­al prob­lem con­cern­ing la­bour law.
20 April 2020
CMS Ex­pert Guide to a Leg­al Roadmap to Can­nabis
22 May 2020
For­eign in­vest­ments in Ger­man life sci­ence com­pan­ies be­come sub­ject to...
In re­sponse to the COV­ID-19 pan­dem­ic, Ger­many has widened the scope of its in­vest­ment con­trol to in­clude nu­mer­ous life sci­ence com­pan­ies. The amend­ments to the For­eign Trade and Pay­ments Or­din­ance ("AWV")...
13 October 2016
CMS Po­land launches law com­pet­i­tion for stu­dents
CMS Po­land is in­vit­ing third, fourth and fifth year law stu­dents to take part in a law com­pet­i­tion. Par­ti­cipants have to come up with the best solu­tion to a leg­al prob­lem con­cern­ing la­bour law.
04 May 2020
EPO Board of ap­peal re­mits to ex­amin­ing di­vi­sion when pri­or art search...
In Mod­el de­term­in­a­tion sys­tem/Ac­cen­ture Glob­al Ser­vices Lim­ited (Case T-1159/15), the board of ap­peal finds that need to per­form a pri­or art search con­sti­tutes a spe­cial reas­on to re­mit the ap­peal ap­plic­a­tion...
CMS ad­vises on Po­lan­d's first large-scale PPP health pro­ject
30 April 2020
USPTO finds an in­ven­tion cre­ated by an AI ma­chine is not pat­entable
The US Pat­ent and Trade Mark Of­fice has found that DABUS is not a per­son and so can­not be con­sidered an in­vent­or of a pat­ent. DABUS is an ar­ti­fi­cial in­tel­li­gence (AI) ma­chine. The USPTO ac­cep­ted the in­dic­a­tion...
Sum­mer in­tern­ships at CMS Po­land
Ever year CMS Po­land of­fers sum­mer in­tern­ships for law stu­dents of IV and V year. This year these one-month in­tern­ships will take place between June and Septem­ber 2015. We plan to of­fer in­tern­ships to circa 40 stu­dents.
17 April 2020
Is a pri­vacy-friendly use of mo­bile ap­plic­a­tions to com­bat COV­ID-19 our...
A Pan-European Ap­proach to the Use of Mo­bile Apps and Mo­bile Data With its Re­com­mend­a­tion of 8 April 2020 on steps and meas­ures to de­vel­op a com­mon ap­proach to the use of mo­bile ap­plic­a­tions and mo­bile...